Articles from Tekla Life Sciences Investors

On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $44,305,054, of which $10,004,278 represents net unrealized appreciation of portfolio securities.

On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is September 29, 2023. The Fund will trade ex-distribution on August 24, 2023.

On June 30, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $67,628,377, of which $60,437,904 represents net unrealized appreciation of portfolio securities.

On May 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is May 25, 2023 and the payable date is June 30, 2023. The Fund will trade ex-distribution on May 24, 2023.

On March 31, 2023, Tekla Life Sciences Investors paid a distribution of $0.33 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $39,622,658, of which $31,823,721 represents net unrealized appreciation of portfolio securities.

Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 20233. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2024. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.

On February 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.33 per share. The record date for the distribution is February 27, 2023 and the payable date is March 31, 2023. The Fund will trade ex-distribution on February 24, 2023.

On November 15, 2022, Tekla Life Sciences Investors declared a distribution of $0.31 per share. The record date for the distribution is November 25, 2022 and the payable date is December 30, 2022. The Fund will trade ex-distribution on November 23, 2022.

On September 30, 2022, Tekla Life Sciences Investors paid a distribution of $0.31 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $44,467,697, of which $16,672,970 represents net unrealized appreciation of portfolio securities.

On August 16, 2022, Tekla Life Sciences Investors declared a distribution of $0.31 per share. The record date for the distribution is August 26, 2022 and the payable date is September 30, 2022. The Fund will trade ex-distribution on August 25, 2022.

On June 30, 2022, Tekla Life Sciences Investors paid a distribution of $0.35 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $27,738,231, of which $20,963,340 represents net unrealized appreciation of portfolio securities.

On May 17, 2022, Tekla Life Sciences Investors declared a distribution of $0.35 per share. The record date for the distribution is May 27, 2022 and the payable date is June 30, 2022. The Fund will trade ex-distribution on May 26, 2022.

On March 31, 2022, Tekla Life Sciences Investors paid a distribution of $0.39 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $78,543,620, of which $70,589,047 represents net unrealized appreciation of portfolio securities.

Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2023. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.

On February 15, 2022, Tekla Life Sciences Investors declared a distribution of $0.39 per share. The record date for the distribution is February 25, 2022 and the payable date is March 31, 2022. The Fund will trade ex-distribution on February 24, 2022.

On December 31, 2021, Tekla Life Sciences Investors paid a distribution of $0.42 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $121,604,114, of which $134,975,348 represents net unrealized appreciation of portfolio securities.

On November 12, 2021, Tekla Life Sciences Investors declared a distribution of $0.42 per share. The record date for the distribution is November 24, 2021 and the payable date is December 31, 2021. The Fund will trade ex-distribution on November 23, 2021.

On September 30, 2021, Tekla Life Sciences Investors paid a distribution of $0.43 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $212,354,715, of which $171,034,424 represents net unrealized appreciation of portfolio securities.

On August 17, 2021, Tekla Life Sciences Investors declared a distribution of $0.43 per share. The record date for the stock distribution is August 27, 2021 and the payable date is September 30, 2021. The Fund will trade ex-distribution on August 26, 2021.

On June 30, 2021, Tekla Life Sciences Investors paid a distribution of $0.41 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $184,606,472, of which $148,920,583 represents net unrealized appreciation of portfolio securities.

On May 18, 2021, Tekla Life Sciences Investors declared a stock distribution of $0.41 per share. The record date for the stock distribution is May 28, 2021 and the payable date is June 30, 2021. The Fund will trade ex-distribution on May 27, 2021.